ArticleBiomimetics (Basel, Switzerland)2026
Calcium Silicate-Based Cements for Vital Pulp Therapy: Integrated Assessment of Radiopacity, Elemental Composition, and 24-h Pulp Cell Responses.
Article in Biomimetics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the radiopacity, elemental composition, cytotoxicity, and cytokine responses of contemporary calcium silicate-based cements containing different radiopacifiers. Four cement materials (NeoMTA2, NeoPUTTY, TheraCal PT, and One-Fil PT) were evaluated. Radiopacity was measured using digital radiography with a 10-step aluminum wedge and expressed in mm Al in accordance with ISO 6876; among three calibration models compared, the quadratic provided the best fit. Elemental composition was analyzed by SEM/EDX. Cytotoxicity was assessed on human dental pulp cells using the MTT assay, and IL-6 and IL-10 levels were quantified by ELISA. One-Fil PT (6.61 mm Al) and NeoPUTTY (6.09 mm Al) showed the highest radiopacity, whereas TheraCal PT (1.61 mm Al) did not meet ISO standards. SEM/EDX revealed tantalum in NeoMTA2 and NeoPUTTY, and zirconium in One-Fil PT and TheraCal PT. NeoPUTTY and NeoMTA2 demonstrated superior cell viability, while One-Fil PT showed the lowest. TheraCal PT and One-Fil PT increased IL-6 expression, whereas NeoPUTTY and NeoMTA2 promoted higher IL-10 levels. Within the limitations of this 24-h in vitro assessment, NeoMTA2 and NeoPUTTY exhibited more favorable short-term cytocompatibility and inflammatory profiles together with adequate radiopacity. These findings require confirmation through long-term in vivo and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.